Portada›Viernes 31 de octubre de 2025
Biomédicas del NASDAQ ante la SEC, viernes 31 de octubre de 2025
Los 23 documentos que 17 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.
← jueves 30 de octubre de 2025 · lunes 3 de noviembre de 2025 →
Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.
Emisiones y dilución
- DFTXDefinium Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
- OCSOculis Holding AG424B5Nueva emisión de acciones con precioEDGAR
- OCSOculis Holding AG424B5Nueva emisión de acciones con precioEDGAR
- QNTMQuantum Biopharma Ltd.424B5Nueva emisión de acciones con precioEDGAR
En el documentoContrasplit de accionestexto original ▸
…provisions of the OBCA. Effective May 24, 2018, we changed our name to “FSD Pharma Inc.” Effective August 15, 2024, we changed our name from “FSD Pharma Inc.” to “Quantum BioPharma Ltd.” On August 15, 2024, we effected a one-for-sixty-five (1-for-65) Reverse Stock Split, pursuant to which our shareholders received one issued and outstanding post-Reverse Stock Split Class A Share or Class B Share, as applicable, in exchange for 65 outstanding pre-Reverse Stock Split Class…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…PROSPECTUS SUPPLEMENT (To Prospectus dated January 4, 2024) Filed pursuant to Rule 424(b)(5) Registration No. 333-276264 QUANTUM BIOPHARMA LTD. UP TO US$21,225,000 CLASS B SUBORDINATE VOTING SHARES We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC , or Wainwright or the Sales Agent, relating to the offering of our Class B Subordinate Voting Shares, or the Class B Shares, pursuant…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…05. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 30, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…05. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 30, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…05. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 30, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SLXNSilexion Therapeutics CorpS-3Capacidad de emisión registradaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…included in its opinion for the years ended December 31, 2024 and 2023 an explanatory paragraph referring to our recurring losses from operations and our cash outflows from operating activities that raise substantial doubt about our ability to continue as a going concern. If we encounter continued issues or delays in the development or commercialization of our product candidates— in particular, SIL 204— or if we incur greater than anticipated expenses, our prior losses…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…maintain compliance with the shareholders’ equity requirement and all other standards for listing on the Nasdaq Capital Market on an ongoing basis. At‑The‑Market Offering Agreement On September 26, 2025, we entered into the At The Market Offering Agreement, dated September 26, 2025 (the “ATM Agreement”), with H.C. Wainwright, as sales agent or principal, providing for the offer and sale from time to time of up to $13,170,000 of our ordinary shares…
- HURATuHURA Biosciences, Inc./NV424B3Prospecto suplementario o de reventaEDGAR
Participaciones y control
Informes y hechos relevantes
- ARTLARTELO BIOSCIENCES, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
- CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
- SCLXScilex Holding Co8-KFin de acuerdo materialEDGAR
- DFTXDefinium Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
- FBLGFibroBiologics, Inc.10-QInforme trimestralEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…generate revenues and may never achieve profitability. Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the unaudited condensed consolidated financial statements. As further described in Note 7, the Company entered into a Standby Equity Purchase Agreement in December 2024…
En el documentoDebilidad material en el control internotexto original ▸
…Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10–Q. During the preparation of our financial statements for the nine months ended September 30, 2025, our management identified a material weakness in our internal control over financial reporting due to a lack of segregation of duties. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial…
- FDMT4D Molecular Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
- HURATuHURA Biosciences, Inc./NV8-KNuevo acuerdo materialEDGAR
- HYPDHYPERION DEFI, INC.8-KNuevo acuerdo materialEDGAR
En el documentoCambio en la dirección de la empresatexto original ▸
…10-K. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In addition, the previously announced resignation of Michael Rowe, the Company's former chief executive officer, will take effect on November 1, 2025. Item 7.01. Regulation FD Disclosure. On October 29, 2025, the Company issued a press release announcing entry into the HAUS Agreement (as defined below). A copy…
- INTSINTENSITY THERAPEUTICS, INC.8-KNuevo acuerdo materialEDGAR
- PHIOPhio Pharmaceuticals Corp.8-KCambio en el consejo o la direcciónEDGAR
- PMCBPharmaCyte Biotech, Inc.8-KCambio en el consejo o la direcciónEDGAR
- RGCRegencell Bioscience Holdings Ltd20-FInforme anual (emisor extranjero)EDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…connection with our financial statements as of and for the year ended June 30, 2025, our independent registered public accounting firm included a going concern explanatory paragraph which stated there was substantial doubt about our ability to continue as a going concern. See “Report of Independent Registered Public Accounting Firm” and Note 2 to the consolidated financial statements included elsewhere in this Annual Report. We incurred total net losses of $3.58 million…
Juntas de accionistas
← jueves 30 de octubre de 2025 · lunes 3 de noviembre de 2025 →
Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.